Skip to content
Master Your Financial Future — Master Your Money — Financial Insights Unveiled — Financial Tech Innovations

Genenta Science Raises $15M for Cancer Treatments

Genenta's $15M raise fuels clinical trials for TemferonTM and combination therapies. The company's focus on one-time monotherapies and potential synergy with other treatments sets it apart in the cancer treatment landscape.

,   and  Administrator
1 min read
This image is clicked in a room, where it looks like Store. There are so many bottles in this image...
This image is clicked in a room, where it looks like Store. There are so many bottles in this image and cans. There is a Banner in the middle which is indicating Supra brand. Bottom right corner there is a logo LM.

Genenta Science Raises $15M for Cancer Treatments

Genenta Science (Nasdaq: GNTA) has successfully raised approximately $15.0 million through a securities offering, closing on October 28, 2025. The company sold 4,285,715 American Depositary Shares (ADSs) at $3.50 per ADS.

Genenta's primary focus is its first product candidate, TemferonTM, designed to express immune-therapeutic payloads within the tumor microenvironment. The company's treatments are intended as one-time monotherapies, but can potentially enhance the efficacy of other approved therapeutics when used in combination.

Genenta has made significant strides in clinical trials. It has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients with an unmethylated MGMT gene promoter. Additionally, the company has initiated a Phase 1/2a metastatic Renal Cell Carcinoma study, which will also explore combinations with immune checkpoint inhibitors.

The company is developing a proprietary hematopoietic stem cells therapy for solid tumor cancers. It plans to use the net proceeds from the offering for working capital and general corporate purposes. Maxim Group LLC and Rodman & Renshaw LLC acted as placement agents for the offering.

Genenta Science's successful fundraising will support its ongoing clinical trials and research into innovative treatments for solid tumor cancers. The company's focus on TemferonTM and its potential as a one-time monotherapy, along with its exploration of combination therapies, positions it well in the competitive landscape of cancer treatments.

Read also:

Related

Latest